MASON, Ohio, April 10, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...
Medical device maker AtriCure (NASDAQ:ATRC) is looking to obtain regulatory clearance to use its AtriClip heart device on stroke patients. The Cincinnati-area company is planning next year to begin a ...
WEST CHESTER, Ohio — AtriCure has received approval in Europe for its AtriClip, a device that protects against clotting during certain heart procedures. Europe’s granting of the CE Mark for the ...
AtriCure, Inc. ATRC recently announced receipt of regulatory approval from China’s National Medical Products Administration (NMPA) for its AtriClip Left Atrial Appendage (LAA) Exclusion System. This ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold ...
Cleveland, OH - The AtriClip Gillinov-Cosgrove Left Atrial Appendage (LAA) Exclusion system (AtriCure, West Chester, OH) has been approved by the US FDA for occlusion of the LAA, under direct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback